Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method
The most accurate way to estimate the glucose metabolic rate (or its influx constant) from (18)F-FDG PET is to perform a full kinetic analysis (or its simplified Patlak version), requiring dynamic imaging and the knowledge of arterial activity as a function of time. To avoid invasive arterial blood...
Gespeichert in:
Veröffentlicht in: | The Journal of nuclear medicine (1978) 2011-04, Vol.52 (4), p.634-641 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 641 |
---|---|
container_issue | 4 |
container_start_page | 634 |
container_title | The Journal of nuclear medicine (1978) |
container_volume | 52 |
creator | Hapdey, Sebastien Buvat, Irene Carson, Joann M Carson, Joan M Carrasquillo, Jorge A Whatley, Millie Bacharach, Stephen L |
description | The most accurate way to estimate the glucose metabolic rate (or its influx constant) from (18)F-FDG PET is to perform a full kinetic analysis (or its simplified Patlak version), requiring dynamic imaging and the knowledge of arterial activity as a function of time. To avoid invasive arterial blood sampling, a simplified kinetic analysis (SKA) has been proposed, based on blood curves measured from a control group. Here, we extend the SKA by allowing for a greater variety of arterial input function (A(t)) curves among patients than in the original SKA and by accounting for unmetabolized (18)F-FDG in the tumor.
Ten A(t)s measured in patients were analyzed using a principal-component analysis to derive 2 principal components describing most of the variability of the A(t). The mean distribution volume of (18)F-FDG in tumors for these patients was used to estimate the corresponding quantity in other patients. In subsequent patient studies, the A(t) was described as a linear combination of the 2 principal components, for which the 2 scaling factors were obtained from an early and a late venous sample drawn for the patient. The original and extended SKA (ESKA) were assessed using fifty-seven (18)F-FDG PET scans with various tumor types and locations and using different injection and acquisition protocols, with the K(i) derived from Patlak analysis as a reference.
ESKA improved the accuracy or precision of the input function (area under the blood curve) for all protocols examined. The mean errors (±SD) in K(i) estimates were -12% ± 33% for SKA and -7% ± 22% for ESKA for a 20-s injection protocol with a 55-min postinjection PET scan, 20% ± 42% for SKA and 1% ± 29% for ESKA (P < 0.05) for a 120-s injection protocol with a 55-min postinjection PET scan, and -37% ± 19% for SKA and -4% ± 6% for ESKA (P < 0.05) for a 20-s injection protocol with a 120-min postinjection PET scan. Changes in K(i) between the 2 PET scans in the same patients also tended to be estimated more accurately and more precisely with ESKA than with SKA.
ESKA, compared with SKA, significantly improved the accuracy and precision of K(i) estimates in (18)F-FDG PET. ESKA is more robust than SKA with respect to various injection and acquisition protocols. |
doi_str_mv | 10.2967/jnumed.110.079079 |
format | Article |
fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00653924v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>859059170</sourcerecordid><originalsourceid>FETCH-LOGICAL-h1649-e432b8d5e4167d9056b8541541e691f2f489c5934b2427362893c545e11265b13</originalsourceid><addsrcrecordid>eNqFkU1P3DAQhi1UxG63_IBeKt8qDgGPv2L3tgIWKq0EUuEcOcmk8dZxtnGCoL--QdBeOCC90mhmnhm9miHkM7BTbnV-totTh_UpzDnL7awDsgQlVKa0zj-QJQMNmVJMLcjHlHaMMW2MOSILDpJDDmZJ_vxAN1Stjz9p0w_UhRGH6Eb_gImOPW2mEOgvH3H0FXXRhafkE_WRgtlkm4srent5921uUHwcMSbfR9o3dGyRJt_tg2881m_nOxzbvv5EDhsXEh6_xhW531zenV9n25ur7-frbdaCljZDKXhpaoUSdF5bpnRplIRZqC00vJHGVsoKWXLJc6G5saJSUiEA16oEsSInL3tbF4r94Ds3PBW988X1els81-azKGG5fHhmv76w-6H_PWEai86nCkNwEfspFZZJmYOQ4l3SqNmqhZzN5JdXcirnd_238O8J4i8qjId1</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>859059170</pqid></control><display><type>article</type><title>Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hapdey, Sebastien ; Buvat, Irene ; Carson, Joann M ; Carson, Joan M ; Carrasquillo, Jorge A ; Whatley, Millie ; Bacharach, Stephen L</creator><creatorcontrib>Hapdey, Sebastien ; Buvat, Irene ; Carson, Joann M ; Carson, Joan M ; Carrasquillo, Jorge A ; Whatley, Millie ; Bacharach, Stephen L</creatorcontrib><description>The most accurate way to estimate the glucose metabolic rate (or its influx constant) from (18)F-FDG PET is to perform a full kinetic analysis (or its simplified Patlak version), requiring dynamic imaging and the knowledge of arterial activity as a function of time. To avoid invasive arterial blood sampling, a simplified kinetic analysis (SKA) has been proposed, based on blood curves measured from a control group. Here, we extend the SKA by allowing for a greater variety of arterial input function (A(t)) curves among patients than in the original SKA and by accounting for unmetabolized (18)F-FDG in the tumor.
Ten A(t)s measured in patients were analyzed using a principal-component analysis to derive 2 principal components describing most of the variability of the A(t). The mean distribution volume of (18)F-FDG in tumors for these patients was used to estimate the corresponding quantity in other patients. In subsequent patient studies, the A(t) was described as a linear combination of the 2 principal components, for which the 2 scaling factors were obtained from an early and a late venous sample drawn for the patient. The original and extended SKA (ESKA) were assessed using fifty-seven (18)F-FDG PET scans with various tumor types and locations and using different injection and acquisition protocols, with the K(i) derived from Patlak analysis as a reference.
ESKA improved the accuracy or precision of the input function (area under the blood curve) for all protocols examined. The mean errors (±SD) in K(i) estimates were -12% ± 33% for SKA and -7% ± 22% for ESKA for a 20-s injection protocol with a 55-min postinjection PET scan, 20% ± 42% for SKA and 1% ± 29% for ESKA (P < 0.05) for a 120-s injection protocol with a 55-min postinjection PET scan, and -37% ± 19% for SKA and -4% ± 6% for ESKA (P < 0.05) for a 20-s injection protocol with a 120-min postinjection PET scan. Changes in K(i) between the 2 PET scans in the same patients also tended to be estimated more accurately and more precisely with ESKA than with SKA.
ESKA, compared with SKA, significantly improved the accuracy and precision of K(i) estimates in (18)F-FDG PET. ESKA is more robust than SKA with respect to various injection and acquisition protocols.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.110.079079</identifier><identifier>PMID: 21421718</identifier><language>eng</language><publisher>United States: Society of Nuclear Medicine</publisher><subject>Algorithms ; Area Under Curve ; Artificial Intelligence ; Carcinoma, Renal Cell - diagnostic imaging ; Fluorodeoxyglucose F18 - pharmacokinetics ; Humans ; Image Processing, Computer-Assisted ; Infusions, Intravenous ; Kidney Neoplasms - diagnostic imaging ; Kinetics ; Lymphatic Metastasis - diagnostic imaging ; Magnetic Resonance Imaging ; Models, Statistical ; Neoplasms - diagnostic imaging ; Neoplasms - metabolism ; Positron-Emission Tomography - methods ; Positron-Emission Tomography - statistics & numerical data ; Radiopharmaceuticals - pharmacokinetics ; Reproducibility of Results ; Tomography, X-Ray Computed</subject><ispartof>The Journal of nuclear medicine (1978), 2011-04, Vol.52 (4), p.634-641</ispartof><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-7053-6471 ; 0000-0002-3967-434X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21421718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00653924$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Hapdey, Sebastien</creatorcontrib><creatorcontrib>Buvat, Irene</creatorcontrib><creatorcontrib>Carson, Joann M</creatorcontrib><creatorcontrib>Carson, Joan M</creatorcontrib><creatorcontrib>Carrasquillo, Jorge A</creatorcontrib><creatorcontrib>Whatley, Millie</creatorcontrib><creatorcontrib>Bacharach, Stephen L</creatorcontrib><title>Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>The most accurate way to estimate the glucose metabolic rate (or its influx constant) from (18)F-FDG PET is to perform a full kinetic analysis (or its simplified Patlak version), requiring dynamic imaging and the knowledge of arterial activity as a function of time. To avoid invasive arterial blood sampling, a simplified kinetic analysis (SKA) has been proposed, based on blood curves measured from a control group. Here, we extend the SKA by allowing for a greater variety of arterial input function (A(t)) curves among patients than in the original SKA and by accounting for unmetabolized (18)F-FDG in the tumor.
Ten A(t)s measured in patients were analyzed using a principal-component analysis to derive 2 principal components describing most of the variability of the A(t). The mean distribution volume of (18)F-FDG in tumors for these patients was used to estimate the corresponding quantity in other patients. In subsequent patient studies, the A(t) was described as a linear combination of the 2 principal components, for which the 2 scaling factors were obtained from an early and a late venous sample drawn for the patient. The original and extended SKA (ESKA) were assessed using fifty-seven (18)F-FDG PET scans with various tumor types and locations and using different injection and acquisition protocols, with the K(i) derived from Patlak analysis as a reference.
ESKA improved the accuracy or precision of the input function (area under the blood curve) for all protocols examined. The mean errors (±SD) in K(i) estimates were -12% ± 33% for SKA and -7% ± 22% for ESKA for a 20-s injection protocol with a 55-min postinjection PET scan, 20% ± 42% for SKA and 1% ± 29% for ESKA (P < 0.05) for a 120-s injection protocol with a 55-min postinjection PET scan, and -37% ± 19% for SKA and -4% ± 6% for ESKA (P < 0.05) for a 20-s injection protocol with a 120-min postinjection PET scan. Changes in K(i) between the 2 PET scans in the same patients also tended to be estimated more accurately and more precisely with ESKA than with SKA.
ESKA, compared with SKA, significantly improved the accuracy and precision of K(i) estimates in (18)F-FDG PET. ESKA is more robust than SKA with respect to various injection and acquisition protocols.</description><subject>Algorithms</subject><subject>Area Under Curve</subject><subject>Artificial Intelligence</subject><subject>Carcinoma, Renal Cell - diagnostic imaging</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Infusions, Intravenous</subject><subject>Kidney Neoplasms - diagnostic imaging</subject><subject>Kinetics</subject><subject>Lymphatic Metastasis - diagnostic imaging</subject><subject>Magnetic Resonance Imaging</subject><subject>Models, Statistical</subject><subject>Neoplasms - diagnostic imaging</subject><subject>Neoplasms - metabolism</subject><subject>Positron-Emission Tomography - methods</subject><subject>Positron-Emission Tomography - statistics & numerical data</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Reproducibility of Results</subject><subject>Tomography, X-Ray Computed</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1P3DAQhi1UxG63_IBeKt8qDgGPv2L3tgIWKq0EUuEcOcmk8dZxtnGCoL--QdBeOCC90mhmnhm9miHkM7BTbnV-totTh_UpzDnL7awDsgQlVKa0zj-QJQMNmVJMLcjHlHaMMW2MOSILDpJDDmZJ_vxAN1Stjz9p0w_UhRGH6Eb_gImOPW2mEOgvH3H0FXXRhafkE_WRgtlkm4srent5921uUHwcMSbfR9o3dGyRJt_tg2881m_nOxzbvv5EDhsXEh6_xhW531zenV9n25ur7-frbdaCljZDKXhpaoUSdF5bpnRplIRZqC00vJHGVsoKWXLJc6G5saJSUiEA16oEsSInL3tbF4r94Ds3PBW988X1els81-azKGG5fHhmv76w-6H_PWEai86nCkNwEfspFZZJmYOQ4l3SqNmqhZzN5JdXcirnd_238O8J4i8qjId1</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Hapdey, Sebastien</creator><creator>Buvat, Irene</creator><creator>Carson, Joann M</creator><creator>Carson, Joan M</creator><creator>Carrasquillo, Jorge A</creator><creator>Whatley, Millie</creator><creator>Bacharach, Stephen L</creator><general>Society of Nuclear Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-7053-6471</orcidid><orcidid>https://orcid.org/0000-0002-3967-434X</orcidid></search><sort><creationdate>201104</creationdate><title>Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method</title><author>Hapdey, Sebastien ; Buvat, Irene ; Carson, Joann M ; Carson, Joan M ; Carrasquillo, Jorge A ; Whatley, Millie ; Bacharach, Stephen L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h1649-e432b8d5e4167d9056b8541541e691f2f489c5934b2427362893c545e11265b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Algorithms</topic><topic>Area Under Curve</topic><topic>Artificial Intelligence</topic><topic>Carcinoma, Renal Cell - diagnostic imaging</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Infusions, Intravenous</topic><topic>Kidney Neoplasms - diagnostic imaging</topic><topic>Kinetics</topic><topic>Lymphatic Metastasis - diagnostic imaging</topic><topic>Magnetic Resonance Imaging</topic><topic>Models, Statistical</topic><topic>Neoplasms - diagnostic imaging</topic><topic>Neoplasms - metabolism</topic><topic>Positron-Emission Tomography - methods</topic><topic>Positron-Emission Tomography - statistics & numerical data</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Reproducibility of Results</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hapdey, Sebastien</creatorcontrib><creatorcontrib>Buvat, Irene</creatorcontrib><creatorcontrib>Carson, Joann M</creatorcontrib><creatorcontrib>Carson, Joan M</creatorcontrib><creatorcontrib>Carrasquillo, Jorge A</creatorcontrib><creatorcontrib>Whatley, Millie</creatorcontrib><creatorcontrib>Bacharach, Stephen L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hapdey, Sebastien</au><au>Buvat, Irene</au><au>Carson, Joann M</au><au>Carson, Joan M</au><au>Carrasquillo, Jorge A</au><au>Whatley, Millie</au><au>Bacharach, Stephen L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>2011-04</date><risdate>2011</risdate><volume>52</volume><issue>4</issue><spage>634</spage><epage>641</epage><pages>634-641</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>The most accurate way to estimate the glucose metabolic rate (or its influx constant) from (18)F-FDG PET is to perform a full kinetic analysis (or its simplified Patlak version), requiring dynamic imaging and the knowledge of arterial activity as a function of time. To avoid invasive arterial blood sampling, a simplified kinetic analysis (SKA) has been proposed, based on blood curves measured from a control group. Here, we extend the SKA by allowing for a greater variety of arterial input function (A(t)) curves among patients than in the original SKA and by accounting for unmetabolized (18)F-FDG in the tumor.
Ten A(t)s measured in patients were analyzed using a principal-component analysis to derive 2 principal components describing most of the variability of the A(t). The mean distribution volume of (18)F-FDG in tumors for these patients was used to estimate the corresponding quantity in other patients. In subsequent patient studies, the A(t) was described as a linear combination of the 2 principal components, for which the 2 scaling factors were obtained from an early and a late venous sample drawn for the patient. The original and extended SKA (ESKA) were assessed using fifty-seven (18)F-FDG PET scans with various tumor types and locations and using different injection and acquisition protocols, with the K(i) derived from Patlak analysis as a reference.
ESKA improved the accuracy or precision of the input function (area under the blood curve) for all protocols examined. The mean errors (±SD) in K(i) estimates were -12% ± 33% for SKA and -7% ± 22% for ESKA for a 20-s injection protocol with a 55-min postinjection PET scan, 20% ± 42% for SKA and 1% ± 29% for ESKA (P < 0.05) for a 120-s injection protocol with a 55-min postinjection PET scan, and -37% ± 19% for SKA and -4% ± 6% for ESKA (P < 0.05) for a 20-s injection protocol with a 120-min postinjection PET scan. Changes in K(i) between the 2 PET scans in the same patients also tended to be estimated more accurately and more precisely with ESKA than with SKA.
ESKA, compared with SKA, significantly improved the accuracy and precision of K(i) estimates in (18)F-FDG PET. ESKA is more robust than SKA with respect to various injection and acquisition protocols.</abstract><cop>United States</cop><pub>Society of Nuclear Medicine</pub><pmid>21421718</pmid><doi>10.2967/jnumed.110.079079</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7053-6471</orcidid><orcidid>https://orcid.org/0000-0002-3967-434X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0161-5505 |
ispartof | The Journal of nuclear medicine (1978), 2011-04, Vol.52 (4), p.634-641 |
issn | 0161-5505 1535-5667 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_00653924v1 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Algorithms Area Under Curve Artificial Intelligence Carcinoma, Renal Cell - diagnostic imaging Fluorodeoxyglucose F18 - pharmacokinetics Humans Image Processing, Computer-Assisted Infusions, Intravenous Kidney Neoplasms - diagnostic imaging Kinetics Lymphatic Metastasis - diagnostic imaging Magnetic Resonance Imaging Models, Statistical Neoplasms - diagnostic imaging Neoplasms - metabolism Positron-Emission Tomography - methods Positron-Emission Tomography - statistics & numerical data Radiopharmaceuticals - pharmacokinetics Reproducibility of Results Tomography, X-Ray Computed |
title | Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A55%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Searching%20for%20alternatives%20to%20full%20kinetic%20analysis%20in%2018F-FDG%20PET:%20an%20extension%20of%20the%20simplified%20kinetic%20analysis%20method&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Hapdey,%20Sebastien&rft.date=2011-04&rft.volume=52&rft.issue=4&rft.spage=634&rft.epage=641&rft.pages=634-641&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.110.079079&rft_dat=%3Cproquest_hal_p%3E859059170%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=859059170&rft_id=info:pmid/21421718&rfr_iscdi=true |